Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Addressing challenges of heterogeneous tumor treatment through bispecific protein-mediated pretargeted drug delivery.

Journal of controlled release : official journal of the Controlled Release Society - 28 Dec 2015

Yang Qi, Parker Christina L, McCallen Justin D, Lai Samuel K

Abstract excerpt

Tumors are frequently characterized by genomically and phenotypically distinct cancer cell subpopulations within the same tumor or between tumor lesions, a phenomenon termed tumor heterogeneity. These diverse cancer cell populations pose a major challenge to targeted delivery of diagnostic and/or therapeutic agents, as the conventional approach of conjugating individual ligands to nanoparticles is often unable to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Chemistry, Pharmaceutical

Share to Drug Carriers

Share to Nanoparticles

Share to Neoplasms

Share to Phenotype

Share to Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 26407672
DOI: 10.1016/j.jconrel.2015.09.040
PMCID: PMC4688191

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Addressing challenges of heterogeneous tumor treatment through bispecific protein-mediated pretargeted drug delivery.PMID 26407672Read ↗

Tumor heterogeneity, clonal evolution, and therapy resistance: an opportunity for multitargeting therapy.Semantic proximity Read ↗

A novel CAR T cell blend targeting PDPN and GD2 to overcome glioblastoma heterogeneitySemantic proximity Read ↗

Multivalent in vivo delivery of DNA-encoded bispecific T cell engagers effectively controls heterogeneous GBM tumors and mitigates immune escapeSemantic proximity Read ↗

Targeting cancer with bispecific antibodies.Semantic proximity Read ↗

A pretargeted nanoparticle system for tumor celllabelingSemantic proximity Read ↗

DNA-Directed Assembly of Multivalent Lipid Nanoparticles for Targeted T Cell Gene DeliverySemantic proximity Read ↗

Bispecific antibodies for immune cell retargeting against cancerSemantic proximity Read ↗

Use of a Single CAR T Cell and Several Bispecific Adapters Facilitates Eradication of Multiple Antigenically Different Solid TumorsSemantic proximity Read ↗

Active specific immunotherapy: using tumor heterogeneity to successfully fight cancer.Semantic proximity Read ↗

Enhancing Cancer Therapy through Polymeric Nano-particles: Targeted Drug Delivery StrategiesSemantic proximity Read ↗

Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistanceSemantic proximity Read ↗

Bispecific antibody targeting of lipid nanoparticlesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.